Enanta Pharmaceuticals will present Phase 2b data showing zelicapavir improves RSV symptom resolution by about a week and reduces hospitalization rates. The oral N-protein inhibitor also demonstrates high resistance barrier in pediatric studies. Presentations will occur at the ESCMID Global 2026 conference in Munich.
Scientists have developed multiple breakthrough delivery systems for gene editing and mRNA therapies, including a simple amino acid supplement that increases delivery 20-fold and a CRISPR gene drive that reverses antibiotic resistance in bacterial populations.
Researchers discovered that adding three common amino acids to lipid nanoparticles dramatically improves mRNA and CRISPR gene editing delivery, boosting efficiency up to 20-fold and raising gene editing success rates from 25% to nearly 90%.
Dianthus Therapeutics will host a conference call on March 9, 2026, to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
Nucleome Therapeutics announces Dr. Michelle Morrow as CSO effective February 23, 2026, bringing two decades of drug discovery experience as the company advances lead candidate NTP464 toward IND enabling studies.
HCW Biologics and WY Biotech closed first-round financing for joint venture Trimmune, granting exclusive worldwide license to develop preclinical TRBC molecule HCW11-006 for $7 million in upfront consideration, with Phase 1 trial planned in China for first half of 2027.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06757426 |
Prospective Observational Study Evaluating the Safety and Efficacy of Immunomodulatory Therapies in Refractory Inflammatory and Autoimmune Diseases |
NOT_YET_RECRUITING | |
| NCT06669702 |
EXercise Therapy in Axial SpA, Inflammation and Biologic Therapy (ExTASI-B) |
RECRUITING | NA |
| NCT06065592 |
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms |
RECRUITING | PHASE1 |
| NCT05662033 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State. |
COMPLETED | PHASE1 |
| NCT05656378 |
A Repository to Study Host-Microbiome Interactions in Health and Disease |
RECRUITING | |
| NCT04987333 |
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants |
COMPLETED | PHASE1 |
| NCT03044873 |
Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin |
COMPLETED | PHASE1 |
| NCT01981785 |
Investigation of Immune Disorders and Deficiencies |
UNKNOWN | |
| NCT01364389 |
A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica |
TERMINATED | PHASE2 |
| NCT00734240 |
Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy Volunteers |
COMPLETED | PHASE1 |
